$GILD Recent Headlines Gilead's high pricing of Sovaldi

New Post Public Reply Private Reply Replies (0) Message Board

Jul 13, 2014 at 10:02 AM

$GILD Recent Headlines

Gilead's high pricing of Sovaldi draws inquiry from Senate committee 1:36 p.m. July 11, 2014 - blogs.marketwatch.com
Bull rolls on, but opportunities start to dwindle 1:52 p.m. July 10, 2014 - The Trading Deck
S&P 500, Nasdaq retest major support 12:12 p.m. July 8, 2014 - Michael Ashbaugh
S&P 500, Nasdaq retest major support 11:57 a.m. July 8, 2014 - Michael Ashbaugh
Growth stocks are doing most bullish thing they can 3:23 p.m. July 1, 2014 - The Trading Deck
Robo-advisors, Syrian strikes and the stock-market shift they signal 6:45 a.m. June 25, 2014 - blogs.marketwatch.com
Health-care inflation heating back up 10:24 a.m. June 24, 2014 - blogs.marketwatch.com
Medtronic’s real problem is innovation, not taxation 6:45 a.m. June 19, 2014 - Tim Mullaney
Rival to Gilead's pricey Sovaldi expected to hit market later this year 7:28 a.m. June 18, 2014 - blogs.marketwatch.com
Tyson falls on Hillshire deal; Apple gains post-split 3:49 p.m. June 9, 2014 - Saumya Vaishampayan
Lobbyists for insurers, big pharma trade barbs over high drug costs 3:10 p.m. June 2, 2014 - blogs.marketwatch.com
Industry titan UnitedHealth misses boom in sector 10:53 a.m. May 29, 2014 - Russ Britt
Gilead says its drug gives hepatitis C patients more cost-effective cure 5:06 p.m. April 30, 2014 - blogs.marketwatch.com
Why a diverse ETF portfolio is right for these times 6:29 a.m. April 30, 2014 - John Prestbo
Internet, biotech could spawn next Apple: Allianz CIO 7:12 a.m. April 29, 2014 - Barbara Kollmeyer
What Obamacare problems? Aetna results not showing any ill effects 12:34 p.m. April 24, 2014 - blogs.marketwatch.com
U.S. stocks tumble; S&P 500 ends 6-day run 4:46 p.m. April 23, 2014 - Anora Mahmudova
Apple, Facebook stuck in red ahead of earnings 3:02 p.m. April 23, 2014 - Saumya Vaishampayan
U.S. stock futures pause after six-session win streak 8:57 a.m. April 23, 2014 - Sara Sjolin
Game day for Facebook and Apple, volume 'signalling the nasty' 6:50 a.m. April 23, 2014 - blogs.marketwatch.com

Biogen's Profit Rolls Amid Recent Drug Launches 6:14 p.m. July 11, 2014 - Investors Business Daily
Senators Investigating Hepatitis C Drug Pricing 5:45 p.m. July 11, 2014 - The Wall Street Journal Interactive Edition
Senators Ask Gilead To Explain Sovaldi Pricing 10:35 a.m. July 11, 2014 - Investors Business Daily
Senators ask Gilead for Sovaldi pricing info 10:09 a.m. July 11, 2014 - Seeking Alpha
Trade-Ideas: Gilead (GILD) Is Today's New Lifetime High Stock 9:46 a.m. July 11, 2014 - TheStreet.com
Stocks Hitting 52-Week Highs 9:13 a.m. July 11, 2014 - benzinga.com
7 Most Heavily Shorted Nasdaq Stocks 8:43 a.m. July 11, 2014 - 247WallSt.com
J.P. Morgan: Johnson & Johnson's Drug Segment May Beat Q2 Street Views 3:31 p.m. July 10, 2014 - benzinga.com
My High Share Buyback And Dividend Growth Portfolio 2nd Quarter 2014 Update 12:05 p.m. July 10, 2014 - Seeking Alpha
14 Insanely Important Biotech/Drug Trading Catalysts for the Rest of 2014 11:54 a.m. July 10, 2014 - TheStreet.com
Gilead Sciences Can Hit Par By The End Of The Year 11:35 a.m. July 10, 2014 - Seeking Alpha
A Pre-Earnings Update On Gilead 10:59 a.m. July 10, 2014 - Seeking Alpha
Gilead Sciences: Cause For Concern? 10:25 a.m. July 10, 2014 - Seeking Alpha
Cramer's Mad Money - The 4 Horsemen Of Biotech Ride On (7/9/14) 6:27 a.m. July 10, 2014 - Seeking Alpha
Jim Cramer's Top Stock Picks: WMB AA BIIB REGN CELG GILD UNUM 6:00 a.m. July 10, 2014 - TheStreet.com
Jim Cramer's 'Mad Money' Recap: Hunting for Bargains 7:53 p.m. July 9, 2014 - TheStreet.com
3 Drugs Stocks Driving The Industry Higher 1:03 p.m. July 9, 2014 - TheStreet.com
Grading Sobek's Mid-Year Biotech Stock Predictions 10:14 a.m. July 9, 2014 - TheStreet.com
Stock Market News for July 09, 2014 - Market News 10:06 a.m. July 9, 2014 - Zacks.com
Hottest Healthcare Stocks Now – SGEN GILD TEVA IRWD 8:30 a.m. July 9, 2014 - InvestorPlace.com

NDA Submission, Results Release Schedules, FDA Grants and Approvals, and Agreements - Analyst Notes on Gilead, Biogen Idec, Amgen, Illumina and MannKind 5:20 a.m. July 4, 2014 - PR Newswire - PRF
Dividends, Mergers, and Study Results - Analyst Notes on Pfizer, Gilead, Pacira, QLT and Agenus 6:30 a.m. July 1, 2014 - PR Newswire - PRF
AIDSVu Releases New Maps that Depict Impact of HIV in American Cities 9:50 a.m. June 27, 2014 - BusinessWire - BZX
Top White House AIDS Official Visits San Francisco Clinic on National HIV Testing Day 9:00 a.m. June 27, 2014 - PR Newswire - PRF
Gilead Submits New Drug Application to Japan’s Pharmaceutical and Medical Devices Agency for Sofosbuvir for Chronic Hepatitis C 3:01 a.m. June 27, 2014 - BusinessWire - BZX
Biotechnology Equities Technical Notes -- Research on StemCells, Gilead Sciences, Galena Biopharma, and Inovio Pharma 7:10 a.m. June 26, 2014 - PR Newswire - PRF
Gilead Sciences to Present at the Wells Fargo Healthcare Conference on Tuesday, June 17 5:00 p.m. June 16, 2014 - BusinessWire - BZX
Gilead Announces Phase 3 Data Showing That the Fixed-Dose Combination of Ledipasvir/Sofosbuvir Achieved 100 Percent Sustained Virologic Response (SVR12) Among Patients with Chronic Hepatitis C in Japan 8:00 p.m. June 15, 2014 - BusinessWire - BZX
Anthera Pharmaceuticals Appoints Dr. Philip Sager to Board of Directors 3:30 p.m. June 13, 2014 - PR Newswire - PRF
Critical Alerts For Ralph Lauren, Rackspace Hosting, Gilead Sciences, Fortinet, and Express Scripts Technology Released By InvestorsObserver 9:31 a.m. June 13, 2014 - PR Newswire - PRF
Prescription for Profit: Pharma-Biotech Industry Continues Mega-Billion Dollar Merger & Acquisition Binge, an Industrial Info News Alert 6:15 a.m. June 11, 2014 - Marketwire
Gilead Sciences to Present at Two Upcoming Investor Conferences on Tuesday, June 10 5:00 p.m. June 9, 2014 - BusinessWire - BZX
Gilead Announces Updated Phase 2 Results for Investigational GS-9973 in Relapsed Chronic Lymphocytic Leukemia 8:30 a.m. June 3, 2014 - BusinessWire - BZX
Stocks Coverage on Biotech Equities -- Research on Gilead Sciences, ARIAD Pharma, Rexahn Pharma, and Geron 7:10 a.m. May 30, 2014 - PR Newswire - PRF
Clinical Study Results, Schedule of Upcoming Conferences, Dividend Declaration, and Services Agreement - Analyst Notes on Gilead, Quest Diagnostics, Sarepta Therapeutics, Incyte and Centene 5:10 a.m. May 28, 2014 - PR Newswire - PRF
AHF: ‘Negligent Corporate Welfare’ Pushes Gilead to Top of S&P 500 5:40 p.m. May 22, 2014 - BusinessWire - BZX
Hepatitis C Therapeutics in Major Developed Markets to 2019 - Outstanding Recent Approvals and Late-Stage Pipeline to Transform Clinical and Commercial Landscape 12:38 p.m. May 22, 2014 - PR Newswire - PRF
Gilead’s Investigational GS-5806 Reduces Viral Load and Clinical Symptoms in Phase 2 Respiratory Syncytial Virus (RSV) Challenge Study in Adults 5:00 p.m. May 20, 2014 - BusinessWire - BZX
Clinical Trial Results, Development Collaboration, Board Appointments, Presentations, and Quarterly Results - Analyst Notes on Gilead, Questcor, Vertex, ARIAD and Puma Biotechnology 7:40 a.m. May 20, 2014 - PR Newswire - PRF
Gilead Sciences to Present at the 2014 UBS Healthcare Conference on Tuesday, May 20 5:00 p.m. May 19, 2014 - BusinessWire - BZX

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fidelis Care Opens $120K Workforce Grants for Aid

Fidelis Care Steps Up Workforce Engagement Fidelis Care's latest move introduces a fresh shot at tackling two birds with one stone—economic and health stability for Medicaid members. The Workforce Pathways to Health and Economic Mobility grants present up to $120,000 in support for New Yorkers, an attempt aimed squarely at reducing the vicious cycle that traps many in...

Life Time's Q3 2026 Results Highlight Solid Growth

Life Time Rolls On With Strong Q3 Performance Sometimes the market hands you pure gold, and that's what Life Time (NYSE: LTH) has right now. They didn't just have a decent quarter; they outright nailed it with a $893.5 million total revenue haul—a hefty 14.2% rise from the prior year. What's driving this ship? Solid growth in membership dues and dynamic personal...

CPSC's Battle Against Dangerous Imports Intensifies

Feldman Sounds Alarm at Bangkok Conference Imagine the chaos if safety took a back seat in our daily lives. Well, that's exactly what's at stake with the influx of dangerous consumer products sailing into our markets. Acting Chairman of the U.S. Consumer Product Safety Commission (CPSC), Peter A. Feldman, gave a no-holds-barred speech on this matter at the INTERPOL...

Huron Consulting Joins S&P SmallCap 600 Lineup Soon

Shuffling the Deck: Huron Consulting Steps In Just when you thought the index shuffle was settled, along comes an eleventh-hour change. Huron Consulting Group is being welcomed with open arms into the S&P SmallCap 600, booting Supernus Pharmaceuticals to the side. Mark November 3 on your calendars—final scorecards before the trading bell could surprise us all. The S&P...

Sol Taps Silberman: Bold New Era for Marketing Shift

Bringing Media Savvy to AI Strategy Dan Silberman, the seasoned media executive from A+E Global Media, just jumped ship to helm marketing and communications at Sol, a firm peddling its ware in AI-enabled business transformation. Maybe you're scratching your head, wondering why the heck it matters. Well, as I see it, this ain't just another name change on a corporate...

2026 Environmental Leadership Awards Unveiled by SP

Celebrating Green Pioneers: SP's Vision in Action Right out of Indianapolis, there's a buzz around the Suppliers Partnership for the Environment's big reveal: the 2026 Environmental Leadership Award recipients. These aren't just plaques to hang on a wall; these awards shout out significant strides in automotive sustainability. Recognized players like Visscher-Caravelle,...

Solink Secures $100M: NYSE Sees Tech and Sports Moves

Folks, it’s a busy day on Wall Street, with Solink leading the charge by landing over a cool $100 million in fresh funding. Let's break this down because when startups pocket nine-digit figures, it's time to pay attention. Solink's Leap Forward Now, what’s Solink doing with all that cash? They're not scrambling for coffee money, that's for sure. Instead, this funding...

Palmdale Propane Expands with Affordable Gas Buy

Propane Power Play in Florida's Market Here's a little tune you don't hear every day: two local businesses tangoing to the beat of expansion without making a public peep about the price. Palmdale Propane, a powerhouse under the Palmdale Oil umbrella, just snapped up Affordable Gas, a local player from Belle Glade, Florida. This acquisition strengthens its grip on the...

Keeping Halloween Safe and Fun with AHN Tips

Trick or Treat the Safe Way Ah, Halloween. A time when you don't just get to pretend to be someone else; you get to pile on the candy like it's a second job. But hold up! Before your pint-sized Dracula sprints into the foggy night, heed some wisdom from the folks at Allegheny Health Network. They aren't just offering another bowl of sugar-coated advice; they've got...

Pozdeutinurad Phase 3 Success Impact on Sobi and Market

Pozdeutinurad's Phase 3 Triumph Ah, the life of biotech—constant ups and downs, but when you hit a homerun, it feels like the market stands still for a second. Pozdeutinurad's recent Phase 3 REDUCE-2 study results are one of those moments for Swedish Orphan Biovitrum AB, or Sobi for short. This study showed some seriously compelling data: clinically meaningful and...